Relief Therapeutics Holding SA (LON:0QKQ)
London
· Delayed Price · Currency is GBP · Price in CHF 2.215
-0.115 (-4.94%)
At close: Jun 6, 2025
LON:0QKQ Revenue
In the year 2024, Relief Therapeutics Holding had annual revenue of 8.42M CHF with 39.52% growth. Relief Therapeutics Holding had revenue of 3.01M in the half year ending December 31, 2023, a decrease of -9.36%.
Revenue
8.42M CHF
Revenue Growth
+39.52%
P/S Ratio
3.49
Revenue / Employee
271.52K CHF
Employees
31
Market Cap
25.87M GBP
Revenue Chart
* This company reports financials in CHF.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 42.56B |
| GSK plc | 31.53B |
| Haleon | 11.23B |
| Smith & Nephew | 4.64B |
| ConvaTec Group | 1.83B |
| Hikma Pharmaceuticals | 2.50B |
| HUTCHMED (China) | 503.39M |
| Genus | 671.60M |
Relief Therapeutics Holding News
- 22 days ago - Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011 - Accesswire
- 4 weeks ago - Relief Therapeutics Publishes 2025 Annual General Meeting Agenda - Accesswire
- 2 months ago - Relief Therapeutics Holding GAAP EPS of -CHF 1.37, revenue of CHF 9.83B - Seeking Alpha
- 2 months ago - Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update - Accesswire
- 3 months ago - Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion - Accesswire
- 4 months ago - Relief Therapeutics to get European patent for investigational drug RLF‑TD011 - Seeking Alpha
- 4 months ago - Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011 - Accesswire
- 5 months ago - Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US - Accesswire